鶹ý

Early Win for PTSD Drug; FDA OKs AI Sleep Diagnostic; Extreme Social Isolation Tool

— News and commentary from the psychiatry world

MedpageToday
Illustration of a brain shaped maze.

ALTO-100, an investigational drug that works to restore plasticity in the brain, yielded a larger reduction in CAPS-5 scores in (PTSD) versus those without the biomarker profile after 4 weeks in a phase IIa study, said Alto Neuroscience.

For patients with psychosis, both and virtual reality mental relaxation were associated with improvements in persecutory delusions, though the researchers noted that they cannot be certain the treatments accounted for the change. (The Lancet Psychiatry)

The algorithm Somnum AI was cleared by the FDA, maker HoneyNaps announced.

Hospital visits for drug- and alcohol-related disorders , a study in Communications Medicine found.

Researchers developed a new tool to assess people for called hikikomori. (World Psychiatry)

People without a history of a psychotic disorder had a significantly higher risk for after an emergency department visit for substance use. (JAMA Psychiatry)

laid out its plan to provide a preliminary summary of how the new ICD-11 classification has changed the diagnosis, treatment, and research of mental illnesses for better or worse.

Training to may have possible mental health benefits. (Science Advances)

A Swedish study found no evidence to suggest that for unipolar depression had a higher risk of treatment-emergent mania/hypomania after 12 weeks. (JAMA Psychiatry)

The family of a man who after being handcuffed and pinned to the floor for 11 minutes reached an $8.5 million settlement. (AP)

U.S. surgeon Carrie Cunningham, MD, spoke out about . (The Guardian)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.